0933-0149P

THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

MAY 2 5 2001

V. P. ZAVIALOV et al.

Conf.:

7527

Appl. No.:

09/424,080

Group:

1646

Filed:

February 14, 2000

Examiner: D. Fitzgerald

For:

COMPOSITIONS FOR ENHANCING

IMMUNOSUPPRESSANTS' PHARMACEUTICAL

ACTIVITIES

SMALL ENTITY TRANSMITTAL FORM

Assistant Commissioner for Patents Washington, DC 20231

May 25, 2001

Sir:

Transmitted herewith is an amendment in the above-identified application.

- Applicant claims small entity status under 37 C.F.R. § 1.27. \boxtimes
- \Box The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.
- The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:

	COCII CUICU	Tale	d as shown	per	ow:		
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	17	_	20	=	0	\$ 9	\$0.00
INDEPENDENT	3	-	3	=	0	\$ 40	\$0.00
FIRST PRESENTATION OF A MULTIPLE CLAIM					\$135	\$0.00	
						TOTAL	\$0.00

	Appl. No. 09/424,080
	Petition for () month(s) extension of time pursuant of time. \$\\$\ 1.17 \text{ and } 1.136(a). \$\\$0.00 \text{ for the extension}
\boxtimes	No fee is required.
	A check in the amount of \$0.00 is enclosed.
	Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate
concu overp fees exten	If necessary, the Commissioner is hereby authorized in this, errent, and future replies, to charge payment or credit any ayment to Deposit Account No. 02-2448 for any additional required under 37 C.F.R. §§1.16 or 1.17; particularly, sion of time fees.
	Respectfully submitted,
	BIRCH, STEWART, KOLASCH & BIRCH, LLP
	By M 4 1 20 36 623 GERARID M. MURPHY, JR. Reg. No. 28,977
GMM/MA 0933-0	P.O. Box 747 A/KW Falls Church, VA 22040-0747 (703) 205-8000
Attachr	nent





UNITED STATE DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO. FILING DATE

FIRST NAMED INVENTOR

ATTORNEY DOCKET NO.

09/424,080

02/14/90

ZAVIALOV

V

933-149PCT

EXAMINER

HM12/0426

BIRCH STEWART KOLASCH & BIRCH PO BOX 747

FALLS CHURCH VA 22040-0747

EXTZGERALD, D

ART UNIT

PAPER NUMBER

1646

DATE MAILED:

04/26/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Application No.: 09/424080 NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirement of such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attentions directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
Applicant Must Provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 Patentln Software Program Support (SIRA) Technical Assistance
/03-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE